The new facility, covering 53,000 square meters, will be the company’s largest investment in advanced quality control to date. It underlines Novo Nordisk’s commitment to ensuring the highest quality standard across its product portfolio.

“This state-of-the-art quality control laboratory highlights Novo Nordisk's global growth journey and our dedication to innovation, says Erik Lorin Rasmussen, senior vice president of Product Supply, Aseptic Manufacturing. “As we expand our manufacturing capacity and anticipate new products to meet the growing global demand, this new quality control facility will play an important role in ensuring the quality of our products and position us to meet the evolving requirements of patients and regulators.”

The new laboratory will serve as a central hub for quality control operations in Denmark, consolidating existing locations into a world-class facility. It is designed to comply with the demands of current and future Good Manufacturing Practice (GMP) and will be able to cater not only to known demand but also provide the flexibility to support future capacity expansions. The facility will use new technologies and digitalisation to automate processes and further strengthen quality control processes.

The facility will be built using sustainable materials wherever possible, including CO₂-reduced concrete for the building superstructure and CO₂-reduced bricks for the façade.

Construction has been initiated and will be finalised in 2027.